Urovant Sciences (UROV) Reports Q2 Loss of $1.23
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Urovant Sciences (UROV) Reports Complete Patient Enrollment in Phase 3 Pivotal Trial Studying Vibegron for Overactive Bladder
November 8, 2018 8:15 AM ESTUrovant Sciences (NASDAQ: UROV) today announced it completed enrollment in its international Phase 3 clinical trial, EMPOWUR, evaluating the safety and efficacy of vibegron as a treatment for adults with symptoms of overactive bladder. Vibegron is an investigational oral beta-3 adrenergic agonist.
I am proud of the progress made since initiating our robust EMPOWUR clinical trial in March of 2018, said Dr. Cornelia Haag-Molkenteller, Chief Medical Officer of Urovant. Exceeding our enrollment ahead of schedule underscores the interest in this trial and reinforces the need for this significantly underserved patient population.
EMPOWUR is a randomized, double-blind... More
